Hydroxyurea

• 

  Subject Areas on Research

  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 
  • A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. 
  • A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • Adherence to hydroxyurea therapy in children with sickle cell anemia. 
  • Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. 
  • Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. 
  • An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. 
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. 
  • Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. 
  • Caring for patients with sickle cell disease in North Carolina. 
  • Cell cycle-dependent expression of thyroid hormone receptor-beta is a mechanism for variable hormone sensitivity. 
  • Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans. 
  • Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. 
  • Cost-effectiveness considerations in the treatment of essential thrombocythemia. 
  • Detailed mechanism of the autoxidation of N-hydroxyurea catalyzed by a superoxide dismutase mimic Mn(III) porphyrin: formation of the nitrosylated Mn(II) porphyrin as an intermediate. 
  • Distribution of repair-incorporated nucleotides and nucleosome rearrangement in the chromatin of normal and xeroderma pigmentosum human fibroblasts. 
  • Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. 
  • Effects of hydroxyurea treatment for patients with hemoglobin SC disease. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Enalapril and hydroxyurea therapy for children with sickle nephropathy. 
  • Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. 
  • Evidence gaps in the management of sickle cell disease: A summary of needed research. 
  • Fertility challenges for women with sickle cell disease. 
  • Full activation of p34CDC28 histone H1 kinase activity is unable to promote entry into mitosis in checkpoint-arrested cells of the yeast Saccharomyces cerevisiae. 
  • Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. 
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. 
  • Hormonal control of oviduct growth and differentiation. 
  • Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. 
  • Hydroxyurea for Sickle Cell Disease: Now Is the Time! 
  • Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. 
  • Hydroxyurea for the treatment of sickle cell disease. 
  • Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. 
  • Hydroxyurea synchronization increases mitotic yield in human glioma cell lines. 
  • Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. 
  • Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia. 
  • Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. 
  • Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease? 
  • Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? 
  • Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. 
  • Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. 
  • Management of Sickle Cell Disease in Children. 
  • Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. 
  • NIH consensus development statement on hydroxyurea treatment for sickle cell disease. 
  • NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. 
  • National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. 
  • Neurofibromatosis type 2. 
  • Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. 
  • PINA is essential for growth and positively influences NIMA function in Aspergillus nidulans. 
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. 
  • Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. 
  • Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. 
  • Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. 
  • Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress. 
  • Protein phosphatase 5 is required for ATR-mediated checkpoint activation. 
  • Pulmonary hypertension and nitric oxide depletion in sickle cell disease. 
  • Regression supports two mechanisms of fork processing in phage T4. 
  • Replication of the Escherichia coli chromosome in RNase HI-deficient cells: multiple initiation regions and fork dynamics. 
  • Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. 
  • Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. 
  • Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. 
  • Selection and analysis of spontaneous reciprocal mitotic cross-overs in Saccharomyces cerevisiae. 
  • Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. 
  • Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. 
  • The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. 
  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. 
  • The role of actin in spindle orientation changes during the Saccharomyces cerevisiae cell cycle. 
• 

  Keywords of People

  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology